An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Researchers compared three popular weight-loss and diabetes drugs — semaglutide, liraglutide, and tirzepatide — to see how they affect heart and metabolic health. The paper is a narrative review, which means the authors looked at and summarized existing studies rather than running a new experiment. They pulled together results from clinical trials and other research to compare benefits and risks for things like blood sugar, weight, blood pressure, cholesterol, and heart-related outcomes. Semaglutide, liraglutide, and tirzepatide are medicines that act like hormones your gut makes to help control appetite and blood sugar. Semaglutide is the active ingredient in Ozempic and Wegovy. Liraglutide is an older cousin sold as Victoza and Saxenda. Tirzepatide (brand name Zepbound or Mounjaro for diabetes, depending on country) is a newer drug that mimics two gut hormones at once. In plain terms: these drugs trick your body into feeling less hungry and manage blood sugar better, which often leads to weight loss and improvements in metabolic markers. What the review actually found is a mix of results across many studies. All three drugs generally improved blood sugar control and helped people lose weight compared with placebo (a dummy treatment). Tirzepatide tended to produce the largest weight losses in head-to-head trials, with semaglutide also strong and liraglutide usually a bit less potent on weight. For heart-related measures — like blood pressure, cholesterol, and some markers of heart disease risk — the drugs often showed modest improvements, but the strongest evidence for lowering actual heart attacks or strokes is mostly for liraglutide and semaglutide in certain studies. Evidence for tirzepatide’s long-term heart outcomes is still emerging because it’s newer. The review mixes results from large clinical trials in people with diabetes or obesity and shorter studies, so the size and strength of the evidence vary. Why this matters: millions of people take these drugs for diabetes and weight management, so knowing how they affect heart health is important. Better blood sugar and weight control usually lowers risk factors for heart disease, and some of these medicines have been shown to reduce the risk of serious heart events in high-risk patients. For someone with type 2 diabetes, obesity, or high cardiovascular risk, these drugs could offer both metabolic and heart benefits. For people mainly chasing weight loss without underlying heart risk, the differences between drugs might influence which one a doctor recommends. There are important caveats. Narrative reviews summarize existing studies but don’t provide new experimental proof, and the quality of included studies varies. Side effects can include nausea, vomiting, diarrhea, and sometimes more serious issues like pancreatitis or gallbladder disease; individual risk profiles differ. Long-term safety data, especially for tirzepatide’s heart outcomes, are still building. These are prescription drugs — not over-the-counter supplements — and they should be used under medical supervision, especially for people with certain medical conditions or taking other medications. Regulatory decisions and guidelines also vary by country. Bottom line: all three drugs improve blood sugar and cause weight loss, tirzepatide and semaglutide tend to give larger weight losses, and some evidence suggests heart-protective effects for semaglutide and liraglutide, while long-term heart data for tirzepatide are still being gathered.
Source: Wiley Online Library